Baxter International is a Deerfield, Illinois-headquartered medical products company that, for most of its modern existence, sat comfortably inside the upper tier of diversified hospital-supply manufacturers. Its footprint spans intravenous infusion pumps and solutions, sterile and non-sterile pharmaceuticals, surgical and critical-care disposables, blood-collection and processing devices, organ-support therapies, parenteral nutrition, hemodialysis and peritoneal dialysis systems, and a broad contract-manufacturing platform. The product catalog reads less like a focused franchise and more like a roll-up of every disposable, fluid-handling, and renal-replacement product the typical hospital uses between admission and discharge. That breadth is simultaneously the source of Baxter's defensive position with hospital procurement groups and the cause of an operating profile that has run below peer-medtech margins for the better part of a decade.
The company is in the middle of the most consequential portfolio reorganisation in its history. In late 2024, Baxter completed the tax-free spin-off of its Kidney Care segment, which was rebranded Vantive and listed independently. The transaction eliminated roughly one-third of consolidated revenue, removed the segment with the most chronic margin headwinds, and sharpened Baxter's identity around its higher-growth Medical Products & Therapies (Hospital Products) franchise and its specialty Advanced Surgery business. The remaining enterprise carries a smaller revenue base but a more coherent operating story: medical pumps, drug delivery, surgical haemostats and sealants, and contract manufacturing all share hospital-channel economics, capital-purchase or annuity-revenue mechanics, and a regulatory and quality infrastructure that is now centralised.
Operational execution is the swing factor. Under CEO Andrew Hider, who assumed the role in late 2024 after a long tenure inside the hospital-products business, management has laid out a multi-year margin-expansion programme built on three pillars: pricing discipline on legacy contracts, product-mix migration toward connected and software-enabled devices such as the Novum IQ large-volume pump, and aggressive cost productivity through a previously announced programme targeting roughly $300 million in run-rate savings by year-end 2026. The first year of execution has been uneven, with a high-profile regulatory remediation at a key sterile-manufacturing facility creating both a volume drag and reputational overhang, and a slower-than-modelled ramp of next-generation pump placements weighing on segment growth.
The investment question, as of mid-2026, is whether the simplified post-spin portfolio is generating enough top-line momentum and operating leverage to justify a premium-to-mature-medtech multiple. Hospital-channel volumes are stable but unspectacular; the connected-pump install base is real but still small relative to the installed base that needs refreshing; the Advanced Surgery franchise is growing at a low-double-digit organic pace but from a base that represents less than a fifth of consolidated revenue; and contract manufacturing continues to grow but does not earn the multiple of branded specialty assets. The bear case rests on slower margin progress, persistent volume softness in legacy IV solutions and dialysate, and continued execution slippage. The bull case rests on pump-platform scale-up, accretive tuck-in M&A, and a 2027 operating-margin print that finally closes the gap to large-cap medtech peers.